| 摘要 |
New medical utilization of alpha -cetocarbonic acid hydrazones and oxines having the general formula (I) wherein I represents an oxygen atom or a group-NH-; Z is a saturated or unsaturated straight or branched chain alkyl group having up to 8 atoms of carbon, optionally substituted once or a plurality of times by a halogen or a hydroxy; R1 is hydrogen, nitrile, formyl or an alkyl group comprising from 1 to 8 C optionally substituted once or a plurality of times by halogen, hydroxy, nitrile, phenyl or carboxyl; R2 represents a saturated or unsaturated straight or branched chain alkyl group with up to 14 atoms of carbon; an alkoxy group comprising from 1 to 6 C or alkylthio having from 1 to 6 C substituted optionally by a lower alkoxy, a cycloalkyl or an aryl; a cycloalkyl group comprising from 3 to 8 C; a phenyl amino; phenyl-N-alkylamino; phenylmercapto; aryl; or aryloxy; these last five substituents being optionally substituted in the aryl part once or a plurality of times by an alkyl comprising from 1 to 6 C, an alkoxy having from 1 to 6 C, a halogen, trifluoromethyl, hydroxy, amino, acetylamino, acetoxy, cyano, nitro or the methylendioxy group; as well as the salts, esters and amides thereof which are physiologically acceptable for the prophylaxis and/or treatment of cardiac and circulatory diseases, particularly ischemic cardiac diseases such as cardiac insufficiency, angina pectoris or myocardial infarction. |
